Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. argenx SE's Research & Development for the
three
months ended in Jun. 2026 was MXN8,480 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was MXN29,686 Mil.
argenx SE (MEX:ARGXN) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
argenx SE Research & Development Related Terms
argenx SE Research & Development Historical Data
* Premium members only.
The historical data trend for argenx SE's Research & Development can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN29,686 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of MXN29,686 Mil mean?
argenx SE (MEX:ARGXN) has a Research & Development of MXN29,686 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on argenx SE and its competitors.
Is argenx SE's Research & Development too high?
argenx SE's current Research & Development is MXN29,686 Mil. Overall, argenx SE has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Research & Development compare to VRTX and REGN?
argenx SE's Research & Development of MXN29,686 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on argenx SE and its competitors. argenx SE's current Research & Development is MXN29,686 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (MEX:ARGXN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN24,598.94, compared to a current price of MXN15,953.15 — trading 35.1% below its estimated fair value. The current Research & Development is MXN29,686 Mil. argenx SE's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For argenx SE (MEX:ARGXN), the current Research & Development is MXN29,686 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (MEX:ARGXN) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of MXN15,953.15 is trading 35.1% below its estimated GF Value™ of MXN24,598.94.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for MEX:ARGXN:
Research & Development: MXN29,686 Mil
GF Value™: MXN24,598.94 vs. price of MXN15,953.15 (35.1% below fair value)
No single metric tells the full story. See the MEX:ARGXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
77GF Score
Get the complete analysis for MEX:ARGXN
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARGXN has been successfully added to your 
